There are currently two major projects that we are focusing for developments:

1. QMS-1001 contains small molecule compounds designed for the therapy of multiple sclerosis by synergistic target effects.

2. QMS-2001 contains small molecule compounds designed for the therapy of cancers through the function of immune modulations.